A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Recruiting

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid TumorsA Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Sponsor:

TScan Therapeutics, Inc.

Code:

NCT05812027

Conditions

Head and Neck Cancer

Cervical Cancer

Non Small Cell Lung Cancer

Melanoma

Ovarian Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Tumor and HLA Profiling

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-29. This information was provided to ClinicalTrials.gov by TScan Therapeutics, Inc. on 2024-08-26.